Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Test Conducted by Tumor Type & End-User The global breast cancer liquid biopsy market will witness a robust CAGR of 19.2%, valued at $124.46 million in 2021, expected to appreciate and reach $604.71 million by 2030, confirms Strategic Market Research. North America had the largest market share, and the fastest-growing region is poised to be Asia-Pacific. As per WCRFI (World Cancer Research Fund International), there were more than 2.26 million new breast cancer cases in women in 2020. Following are the reasons associated with an increased risk of breast cancer in women: Early menarche (before the age of 12) Late natural menopause (after the age of 55) Not bearing a Child First pregnancy over the age of 30 Ionizing radiation exposure from medical treatment such as X-rays – particularly during puberty and hormone therapy. Breast Cancer is Diagnosed Using a Variety of Tests and Procedures. Breast examination. Mammogram. Breast ultrasound. Biopsy (Removing a sample of breast cells for testing) Breast magnetic resonance imaging (MRI). Biopsies are classified into Tissue biopsy and Liquid Biopsy In Tissue biopsy, a tissue sample is taken from the body; however, liquid biopsy investigates cancer cells in the blood sample. According to a study published in NCBI, Liquid biopsy has high specificity than Tissue Biopsy. Liquid biopsy is non-invasive, rapid, precise, and especially real-time. It can also overcome the heterogeneity of tumours and may replace tissue biopsy in the future. Tissue biopsies are fully utilized when a known tumour's location is confirmed and available for extraction. Breast Cancer liquid biopsy screening is best used to identify mutations in metastatic cancer and track changes in mutations for treatment. Liquid biopsy is not currently used as a routine test in clinical practice. According to a recent study conducted by Agency for Healthcare Research and Quality, more than 50% of all breast biopsies use a core-needle technique. However, the potential applications of Liquid biopsy are rapidly growing: Some of the applications include Diagnostic genomic profiling Monitoring of radicality in surgical outcomes Evaluating either response/resistance to systemic treatments Quantifying minimal residual disease. According to WHO, Breast cancer had been diagnosed in 7.8 million women in the previous five years as of 2020, making it the most common cancer in the world. Breast cancer causes more disability-adjusted life years (DALYs) in women worldwide than any other type of cancer. In addition, female breast cancer accounts for 15.2% of all new cancer cases in the USA. According to Fred Hutchinson Cancer Center, Breast cancer will kill an estimated 5.8 million women by 2025, with a disproportionate percentage occurring in low-resource settings. Higher breast cancer case fatality rates in low-resource settings have been attributed to a lack of awareness regarding the benefits of early detection and treatment, late-stage diagnosis and limited access to appropriate care. Key Industry Drivers - Technology, Use of Liquid Biopsy, Non-Invasive Procedures and R&D Facility As per research that was published by the Centres for Disease Control and Prevention (CDCP), female breast cancer is expected to witness the largest increase in incident cases (52%) by 2050. Key factors that promote the growth of the breast cancer liquid biopsy market are the rise in prevalence of breast cancer, technological advancements in breast cancer, use of liquid biopsy instruments, increase in preference for non-invasive procedures, advantages of over solid tumour biopsy, and increase in patient awareness towards minimally invasive breast cancer liquid biopsy procedures. According to Globocan (Global Cancer Observatory) 2020, Out of all deaths due to cancers, Breast cancer accounted for 7% of deaths. Moreover, other contributing factors are the rise in funding for R&D in breast liquid biopsy, favourable initiatives undertaken by governments and global health organizations, and an increase in breast cancer liquid biopsy reagents approvals. Restraints - Lack of Accessibility, Awareness and Skilled Professionals, Late-stage Diagnosis Due to the lack of access and awareness regarding breast cancer in underdeveloped countries, the market growth is hindered extensively. Also, there is a paucity of skilled professionals and instances of late-stage diagnosis. Opportunities Comprehensiveness- With the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management, including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment. However, traditional cancer detection methods such as tissue biopsy are not comprehensive enough to capture the entire genomic landscape of breast tumours. FDA Approved-The Food and Drug Administration (FDA) has expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumour cells that have been released into the blood. Regulatory Approvals-In response both to regulatory restrictions imposed by the Clinical Laboratory Improvement Amendments of 1988 and to managed care infiltration, It seems likely that physicians' office laboratories (POLs) and hospital laboratories will continue to reduce test volumes. In contrast, commercial reference laboratories will thrive through contracting with Managed Care Organisations (MCOs). Global Initiatives- Breast Cancer Initiative 2.5 (BCI2.5), a global campaign to reduce disparities in breast cancer outcomes and improve access to breast health care for 2.5 million women by 2025, is getting immense support. Technological Innovations-Female breast cancer mortality has declined in three decades by 42% because of earlier diagnosis, increased awareness, mammography screening, and improvements in treatment. According to American Cancer Society estimates 2022, For women, breast cancer accounted for almost 31% of all new diagnoses and was the second leading cause of death (15%) in the US. It is most common among women aged 20 to 59 years. The Breast Cancer liquid biopsy market growth is likely to benefit from increased regulatory approvals from the governmental bodies worldwide. Moreover, Liquid biopsy has many clinical applications as an alternate approach for detecting breast cancer. A survey suggests that liquid biopsy breast cancer recurrence is low in patients with detectable circulating tumour cells in their blood samples. All these factors can cater to many opportunities for market growth in the future. Market Analysis Of Different Segments Covered in the Report By Indicators (Circulating Biomarkers) Circulating Tumor Cells (CTCs) Circulating Cell-free DNA (cfDNA) Extracellular Vesicles Other Circulating Biomarkers Based on End-users Hospitals Physician Laboratories Reference Laboratories Public Health Laboratories Research Institutes Small Molecular Laboratories Pathology Laboratories By Region North America Europe Asia-Pacific Middle-East and Africa South America Segments Analysis & Insights By Indicators, the Circulating Cell-free DNA (cfDNA) Segment is expected to hold a major Market Share. Over the past decade, circulating tumor cells (CTCs) and cell-free DNA (cfDNA) have been identified as potential blood-based biomarkers capable of providing prognostic and predictive information in cancer. The non-invasive approach to monitoring tumour molecular profiling in real-time at multiple time points, the ability to detect emerging genomic alterations associated with drug resistance, and the potential to clarify cancer prognosis and diagnosis of cancer recurrence or progression are the reasons attributed to the growth of this segment. By End-User, the Reference Laboratories Segment is the largest global breast cancer liquid biopsy market segment. According to Medicare, a "Reference laboratory" is the laboratory that receives a specimen from another laboratory and performs one or more tests on such specimen. Most of the tests performed are referred from physician's offices, private practitioners, hospitals, and other healthcare facilities like nursing homes. Reference labs lead the segment due to the following reasons: They Perform High volume routine and speciality testing. They carry out difficult procedures beyond the capacities of clinic lab facilities. They Charge Low Rates due to economies of scale. By Region, North America is projected to hold a Significant Breast Cancer liquid biopsy market share. The reasons are attributed to the rising incidence of breast cancer in this region and the growing demand for non-invasive therapy, advanced diagnostic technologies and better health infrastructure. According to National Cancer Institute, while breast cancer survival rates are over 80% in North America, they can fall below 40% in some low-income countries. This disparity between nations can be largely attributed to the lack of early detection programs in LMICs. Breast Cancer Liquid Biopsy Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 124.46 Million Revenue forecast in 2030 USD 604.71 Million Growth rate CAGR of 19.2% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2020 - 2030) Segmentation By Indicators, By End-Users and By Region By Indicators Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles By End-User Hospitals, Physician’s Laboratory, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratory By Region Asia Pacific, North America, Europe, South America, Middle –East Africa and LAMEA Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Johnson & Johnson (Janssen Diagnostics), F. Hoffmann-La Roche Ltd, Qiagen, Janssen, Diagnostics, Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences Inc., Biodesix, Illumina Inc., Bio-Rad Laboratories, Biocept Inc,) Pricing and purchase options Customized buying options are available to meet your exact research needs. Breast Cancer Liquid Biopsy Market Competitive Landscape Analysis Competitive landscape analysis, which details the most significant competitors operating in a global market. The comparison is based on overall revenue generation, market initiatives, company overview, R&D investment, production analysis, value chain optimization, market share financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, and other variables. Johnson & Johnson (Janssen Diagnostics) F. Hoffmann-La Roche Ltd Bio-Rad Laboratories Biocept Inc Qiagen Janssen Diagnostics Guardant Health Inc. Myriad Genetics Adaptive Biotechnologies Epic Sciences Fluxion Biosciences Inc. Biodesix Illumina Inc. Recent Developments In March 2021, The WHO introduced a Global Breast Cancer Initiative to reduce global breast mortality by 2.5 per cent by 2040. The initiative aims to reduce 2.5 million global deaths, particularly in low-income countries, where the progress in tackling the disease has been relatively slow. WHO intends to guide governments across the world on ways to strengthen systems for diagnosing and treating breast cancer. In December 2020, Biocept's Target SelectorTM Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in a Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center. Detecting HER2 changes with Target SelectorTM aids physicians in reevaluating treatment options for patients with metastatic breast cancer. In October 2020, the US FDA expanded its clearance for two liquid biopsy tests in this country—Guardant Health's Guardant360 CDx and Foundation Medicine's FoundationOne Liquid CDx—for use as companion diagnostic tests and general tumour profiling for certain non-small cell lung, prostate, breast, and ovarian cancers, according to an NIH National Cancer Institute news release. In May 2019, to encourage the role of liquid biopsy in Breast Cancer management, the US FDA approved the Therascreen PIK3CA RGQ polymerase chain reaction assay as a companion diagnostic assay to detect PIK3CA mutations in breast cancer for both tissue and liquid biopsies. The therascreen PIK3CA Kit is the first companion diagnostic assay to receive FDA pre-market approval to identify activating mutations in the gene in any cancer indication. . Various Devices that Key Market Leaders Develop Product Function Key players QX200 Droplet Digital PCR System Quantifies target DNA or RNA molecules using EvaGreen or TaqMan Hydrolysis Probes Bio-Rad Laboratories AVENIO ctDNA Analysis Kits (RUO) Tumor profiling and surveillance & monitoring F. Hoffmann-La Roche Ltd CellSearch Capture and count CTCs to determine the prognosis of patients with cancer (only technique approved by the FDA to detect CTCs) Johnson & Johnson Target Selector High Accurate When Used for Monitoring the Progression of Metastatic Breast Cancer Biocept Inc Frequently Asked Question About This Report What is the liquid biopsy market? The liquid biopsy market is the cancer diagnosis market that is expected to rise fivefold over the next ten years. This is being pushed by the growing customer preference for non-invasive diagnostic technologies around the world. How much does a liquid biopsy cost? The average cost for testing is about $1,200 per patient, which sums up to roughly $14,000 for a tissue biopsy. What is the aim of a liquid biopsy test for breast cancer? A liquid biopsy test for breast cancer investigates circulating cancer cells (CTCs) or fragments of circulating tumour DNA (ctDNA) that can be excreted from a tumour. The test helps to detect cancer at an early stage. What are contemporary trends in liquid biopsy metastatic breast cancer? In metastatic breast cancer (MBC), blood-based diagnostics have become a significant focus of oncological research in the last two decades for cancer liquid biopsy companies Detection of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) has the potential to improve prognosis assessment and complement standard therapy monitoring tools. How big is the breast cancer liquid biopsy market? The global breast cancer liquid biopsy market size was $ 124.46 Mn in 2021 and is predicted to reach $ 604.71 Mn by 2030, with a CAGR of 19.2 %. What are the breast cancer liquid biopsy market growth? The global breast cancer liquid biopsy market is expected to grow at a compound annual growth rate (CAGR) of 19.2 % from 2021 to 2030 to reach USD 604.71 Million by 2030. Sources https://www.wcrf.org/cancer-trends/breast-cancer-statistics/ https://www.ncbi.nlm.nih.gov/books/NBK246882/ https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/epidemiology/breast-cancer-initiative-2-5.html https://ascopubs.org/doi/abs/10.1200/jgo.2016.004556 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Breast Cancer Liquid Biopsy Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Breast Cancer Liquid Biopsy Market 4.2.1 Market, 2021 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021 - 2030 (USD Million) 4.4 Product Type Business Analysis 4.4.1 Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 4.5 Procedure Business Analysis 4.5.1 Market, By End-users, 2021 - 2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 Market PEST analysis 4.8.2 Market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2021) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Facial Implants Manufacturing Sites, Area Served, Product Type 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Breast Cancer Liquid Biopsy Market: By Indicators (Circulating Biomarkers) Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Circulating Tumor Cells (CTCs) 7.3.1. Circulating Tumor Cells (CTCs) market, 2021 - 2030 (USD Million) 7.4. Circulating Cell-free DNA (cfDNA) 7.4.1. Circulating Cell-free DNA (cfDNA) market, 2021 - 2030 (USD Million) 7.5. Extracellular Vesicles 7.5.1. Extracellular Vesicles market, 2021 - 2030 (USD Million) 7.6. Other Circulating Biomarkers 7.6.1. Other Circulating Biomarkers market, 2021 - 2030 (USD Million) 8. Global Breast Cancer Liquid Biopsy Market: Based on End-users 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hospitals 8.3.1. Hospitals market, 2021 - 2030 (USD Million) 8.4. Physician Laboratories 8.4.1. Physician Laboratories market, 2021 - 2030 (USD Million) 8.5 Reference Laboratories 8.5.1 Reference Laboratories market, 2021 - 2030 (USD Million) 8.6 Public Health Laboratories 8.6.1 Public Health Laboratories market, 2021 - 2030 (USD Million) 8.7 Research Institutes 8.7.1 Research Institutes market, 2021 - 2030 (USD Million) 8.8 Small Molecular Laboratories 8.8.1 Small Molecular Laboratories market, 2021 - 2030 (USD Million) 8.9 Pathology Laboratories 8.9.1 Pathology Laboratories market, 2021 - 2030 (USD Million) 9. Global Breast Cancer Liquid Biopsy Market: Regional Outlook 9.1 North America 9.1.1. North America Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.1.4. North America Market, By End-users, 2021 - 2030 (USD Million) 9.1.5. North America Market, by Country, 2021 - 2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.1.4.2.2. Canada Market, By Region, 2021 - 2030 (USD Million) 9.1.4.2.3. Canada Market, By END-USERS, 2021 - 2030 (USD Million) 9.2. Europe 9.2.1. Europe Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.2.2. Europe Market, By End-users, 2021 - 2030 (USD Million) 9.2.5. Europe Market, by country, 2021 - 2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.2.4.1.2. U.K. Market, By END-USERS, 2021 - 2030 (USD Million) 9.2.4.1.3. U.K. Market, by Region, 2021 - 2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.2.4.2.2. Germany Market, By End-users, 2021 - 2030 (USD Million) 9.2.4.2.3. Germany Market, by Region, 2021 - 2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.2.4.3.2. France Market, By Region, 2021 - 2030 (USD Million) 9.2.4.3.3. France Market, By End-users, 2021 - 2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.2.4.4.2. Rest of Europe Market, By Region, 2021 - 2030 (USD Million) 9.2.4.4.3. Rest of Europe Market, By End-users, 2021 - 2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.2. Asia Pacific Market, By End-users, 2021 - 2030 (USD Million) 9.3.5. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.4.1.2. China Market, By Region, 2021 - 2030 (USD Million) 9.3.4.1.3. China Market, By End-users, 2021 - 2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.4.2.2. India Market, By Region, 2021 - 2030 (USD Million) 9.3.4.2.3. India Market, By End-users, 2021 - 2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.4.3.3. Japan Market, By End-users, 2021 - 2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.4.4.3. South Korea Market, By End-users, 2021 - 2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC Market, By End-users, 2021 - 2030 (USD Million) 9.4. Latin America 9.4.1. Latin America Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.4.3. Latin America Market, By End-users, 2021 - 2030 (USD Million) 9.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.4.4.1.3. Brazil Market, By End-users, 2021 - 2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.4.4.2.3. Mexico Market, By End-users, 2021 - 2030 (USD Million) 9.4.4.3. Rest of Latin America 9.4.4.3.1. Rest of the Latin America Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.4.4.3.3. Rest of the Latin America Market, By End-users, 2021 - 2030 (USD Million) 9.5. MEA 9.5.1. MEA Market, By Indicators (Circulating Biomarkers), 2021 - 2030 (USD Million) 9.5.3. MEA Market, By End-users, 2021 - 2030 (USD Million) 10. Competitive Landscape 10.1 Johnson & Johnson (Janssen Diagnostics) 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. Product Portfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. F. Hoffmann-La Roche Ltd 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Bio-Rad Laboratories 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Biocept Inc. 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Qiagen 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Janssen Diagnostics 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. Guardant Health Inc. 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. Myriad Genetics. 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. Adaptive Biotechnologies 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. Epic Sciences 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. Fluxion Biosciences Inc. 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development 10.12. Biodesix 10.12.1. Company overview 10.12.2. Financial performance 10.12.3. Product Portfolio Analysis 10.12.4. Business Strategy & Recent Development 10.13. Illumina Inc. 10.13.1. Company overview 10.13.2. Financial performance 10.13.3. Product Portfolio Analysis 10.13.4. Business Strategy & Recent Development List of Tables (65 Tables) TABLE 1. Market, By Indicators (Circulating Biomarkers), 2021-2030 (USD Million) TABLE 2. Market FOR Circulating Tumor Cells (CTCs), BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Circulating Cell-free DNA (cfDNA), BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Extracellular Vesicles, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Other Circulating Biomarkers, BY REGION, 2021-2030 (USD Million) TABLE 6. Market, BY END-USERS, 2021-2030 (USD Million) TABLE 7. Market FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Physician Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Reference Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 10. Market FOR Public Health Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 11. Market FOR Research Institutes, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Small Molecular Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Pathology Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 10. Market, BY REGION, 2021-2030 (USD Million) TABLE 11. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 12. NORTH AMERICA Market, By Indicators (Circulating Biomarkers), 2021-2030 (USD Million) TABLE 13. NORTH AMERICA Market, BY END-USERS, 2021-2030 (USD Million) TABLE 14. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 15. EUROPE Market, By Indicators (Circulating Biomarkers), 2021-2030 (USD Million) TABLE 16. EUROPE Market, BY END-USERS, 2021-2030 (USD Million) TABLE 17. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 18. ASIA-PACIFIC Market, By Indicators (Circulating Biomarkers), 2021-2030 (USD Million) TABLE 19. ASIA-PACIFIC Market, BY END-USERS, 2021-2030 (USD Million) TABLE 20. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 21. LAMEA Market, By Indicators (Circulating Biomarkers), 2021-2030 (USD Million) TABLE 22. LAMEA Market, BY END-USERS, 2021-2030 (USD Million) TABLE 23. Johnson & Johnson (Janssen Diagnostics): COMPANY SNAPSHOT TABLE 24. Johnson & Johnson (Janssen Diagnostics): OPERATING SEGMENTS TABLE 25. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT TABLE 26. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS TABLE 27. Bio-Rad Laboratories: COMPANY SNAPSHOT TABLE 28. Bio-Rad Laboratories: OPERATING SEGMENTS TABLE 29. Biocept Inc:COMPANY SNAPSHOT TABLE 30. Biocept Inc: OPERATING SEGMENTS TABLE 31. Qiagen: COMPANY SNAPSHOT TABLE 32. Qiagen: OPERATING SEGMENTS TABLE 33. Janssen Diagnostics: COMPANY SNAPSHOT TABLE 34. Janssen Diagnostics: OPERATING SEGMENTS TABLE 35. Guardant Health Inc.: COMPANY SNAPSHOT TABLE 36. Guardant Health Inc.: OPERATING SEGMENTS TABLE 37. Myriad Genetics: COMPANY SNAPSHOT TABLE 38. Myriad Genetics: OPERATING SEGMENTS TABLE 39. Adaptive Biotechnologies: COMPANY SNAPSHOT TABLE 40. Adaptive Biotechnologies: OPERATING SEGMENTS TABLE 41. Epic Sciences: COMPANY SNAPSHOT TABLE 42. Epic Sciences: OPERATING SEGMENTS TABLE 43. Fluxion Biosciences Inc: COMPANY SNAPSHOT TABLE 44. Fluxion Biosciences Inc: OPERATING SEGMENTS TABLE 45. Biodesix: COMPANY SNAPSHOT TABLE 46. Biodesix: OPERATING SEGMENTS TABLE 47. Illumina Inc: COMPANY SNAPSHOT TABLE 48. Illumina Inc: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Breast Cancer Liquid Biopsy Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Product-Based Estimation Figure 6 Top 13 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Facial Implants, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Facial Implants, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Indicators (Circulating Biomarkers), 2019 vs. 2025 (USD Million) Figure 12 Market Share, By END-USER 2019 vs. 2025 Figure 13 Geographical Snapshot of the Market Figure 14 Circulating Cell-free DNA to Witness Higher CAGR in Market for Indicators (Circulating Biomarkers) Segment during Forecast Period. Figure 15 Reference Laboratories to Witness Higher CAGR in Market for End-Users during Forecast Period. Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 17 Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Market Snapshot Figure 19 Asia Pacific: Market Snapshot Figure 20 Vendor Dive: Evaluation Overview